DiaMonTech collects 5 million euros

Berlin, 4 September 2018

DiaMonTech GmbH, a start-up specializing in non-invasive blood glucose measurement methods, has successfully completed its second financing round. In total, the company will receive around 5 million euros from old and new investors. The IBB Beteiligungsgesellschaft from Berlin, the Japanese electronics group Macnica and the Chinese venture capitalist Jindong Capital are the largest investors. DiaMonTech intends to use the money to advance the development of non-invasive blood glucose monitoring with its patented optical method.

About DiaMonTech

Founded in Berlin, Germany, in 2015, DiaMonTech is a medical technology company committed to improving health outcomes for people with diabetes and empowering them to take control of their lifelong health. Its pioneered and patented non-invasive “no prick” photothermal detection technology is fast and painless and doesn’t require needles or test strips. An industry first, DiaMonTech monitors the actual glucose molecules in skin, providing users with a more comprehensive and accurate reading comparable to invasive commercial devices. DiaMonTech achieved 99.1% accuracy in a test study with 100 people studied, received the CE mark as a medical device in April 2019 and is currently under FDA review. To support its mission, DiaMonTech is led by a world-class team of scientists, researchers and healthcare experts. 

More information about DiaMonTech can be found at www.diamontech.de.

Press contact
Markus Teuber
E-mail: hello@diamontech.de

The future begins now!

Stay tuned and get updates.

We are working hard in our lab day and night but it takes some time to develop a new medical device. Subscribe to our newsletter to get the latest news.

Notify me
Press
news@diamontech.de
INQUIRIES
hello@diamontech.de
Investor relations
ir@diamontech.de